Khalid Islam

Dr. Khalid Islam cofounded Gain and has served as chairman of the board of directors since 2017. Dr. Islam has over 30 years of experience in the biotechnology and pharmaceutical industries. He is currently the chairman of the board of directors of Fennec Pharmaceuticals and Minoryx Therapeutics, advisor to Kurma Biofund, as well as a director of Processa Pharmaceuticals. Dr. Islam previously served as chairman and chief executive officer of Gentium, where, under his leadership, Defitelio was granted marketing authorization and the company went from a $25 million valuation to a $1 billion all-cash merger with Jazz Pharmaceuticals. He also developed his career as president and chief executive officer of Arpida, where he transitioned the early-stage startup to an SWX-listed company and raised $300 million between their initial public offering and follow-ons. In addition, Dr. Islam held various positions at HMR & MMD (now Sanofi-Aventis) and he also worked in academia at Imperial College, University of London, and Milan University, where he was a contract professor. He has also previously served as a director of Immunomedics, Karolinska Development, MolMed, OxThera, Rheoscience, PCovery, Adenium, and C10 Pharma. Dr. Islam received his Ph.D. from Imperial College, University of London.